Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
輝瑞公司報告稱第三期潰瘍性結腸炎試驗患者入組人數減少15％；入組人數從912人減少至772人；試驗仍在進行但不再招募；首要完成日期修訂爲2026年7月20日
Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
輝瑞公司報告稱第三期潰瘍性結腸炎試驗患者入組人數減少15％；入組人數從912人減少至772人；試驗仍在進行但不再招募；首要完成日期修訂爲2026年7月20日
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。